|
hepatocellular carcinoma |
67 |
|
animals |
30 |
|
cell line, tumor |
28 |
|
humans |
27 |
|
liver transplantation |
26 |
|
mice |
23 |
|
cell proliferation |
21 |
|
mice, nude |
21 |
|
male |
20 |
|
apoptosis |
19 |
|
medical sciences |
18 |
|
reverse transcriptase polymerase chain reaction |
18 |
|
liver cancer |
17 |
|
adult |
16 |
|
hcc |
16 |
|
metastasis |
16 |
|
disease models, animal |
15 |
|
hepatectomy |
15 |
|
transfection |
15 |
|
up-regulation |
15 |
|
aged |
14 |
|
cell movement |
14 |
|
female |
14 |
|
immunohistochemistry |
14 |
|
middle aged |
14 |
|
peptidyl-prolyl-isomerase |
14 |
|
pin1 |
14 |
|
rats |
14 |
|
surgery |
14 |
|
β-catenin |
14 |
|
adolescent |
13 |
|
gastroenterology medical sciences |
13 |
|
liver neoplasms - metabolism - pathology |
13 |
|
arginine methylation |
12 |
|
cancer stemness |
12 |
|
carcinoma, hepatocellular - metabolism - pathology |
12 |
|
disease progression |
12 |
|
down-regulation |
12 |
|
inflammation |
12 |
|
neoplasm transplantation |
12 |
|
rats, sprague-dawley |
12 |
|
beta catenin |
11 |
|
carcinoma, hepatocellular - etiology - genetics - metabolism |
11 |
|
carrier proteins - metabolism |
11 |
|
cyclin d1 - biosynthesis - genetics |
11 |
|
cytoskeletal proteins - genetics |
11 |
|
gene expression profiling |
11 |
|
immunotherapy |
11 |
|
peptidylprolyl isomerase - biosynthesis - genetics |
11 |
|
recurrence |
11 |
|
trans-activators - genetics |
11 |
|
angiogenesis |
10 |
|
antigens, cd - genetics - metabolism |
10 |
|
berberine |
10 |
|
dna primers |
10 |
|
neoplasm invasiveness |
10 |
|
sphingosine - analogs & derivatives |
10 |
|
tumor recurrence |
10 |
|
aged, 80 and over |
9 |
|
cancer cell culture |
9 |
|
carcinoma, hepatocellular - genetics |
9 |
|
cell line |
9 |
|
down-regulation - drug effects |
9 |
|
epigenetics |
9 |
|
fty720 |
9 |
|
gene knockdown techniques |
9 |
|
gpx3 |
9 |
|
hipsc-mscs |
9 |
|
immunosuppressive agents - therapeutic use |
9 |
|
invasiveness |
9 |
|
liver - metabolism - pathology |
9 |
|
liver neoplasms - genetics |
9 |
|
liver neoplasms - genetics - metabolism - pathology |
9 |
|
mice, inbred balb c |
9 |
|
nafld |
9 |
|
nash |
9 |
|
non-viral liver disease |
9 |
|
propylene glycols - pharmacology |
9 |
|
transcription factors - metabolism |
9 |
|
tumor cells, cultured |
9 |
|
tumor-initiating cells |
9 |
|
tumorigenesis |
9 |
|
base sequence |
8 |
|
carcinoma, hepatocellular - enzymology - pathology |
8 |
|
carcinoma, hepatocellular - genetics - metabolism |
8 |
|
carcinoma, hepatocellular - metabolism - pathology - secondary |
8 |
|
cell division - physiology |
8 |
|
cell proliferation - drug effects |
8 |
|
chemokine cxcl1 - physiology |
8 |
|
cyclin a2 |
8 |
|
cyclin-dependent kinase inhibitor p16 - genetics - metabolism |
8 |
|
focal adhesion kinase 2 - metabolism |
8 |
|
glycoproteins - deficiency - genetics - metabolism |
8 |
|
glycoproteins - genetics - metabolism |
8 |
|
hbv integration |
8 |
|
heme oxygenase-1 |
8 |
|
inhibitor of differentiation protein 1 |
8 |
|
interleukin-8 - deficiency - genetics - physiology |
8 |
|
ischemia-reperfusion injury |
8 |
|
liver |
8 |
|
liver - anatomy & histology |
8 |
|
liver graft injury |
8 |
|
liver neoplasms - enzymology - pathology |
8 |
|
liver neoplasms - genetics - metabolism |
8 |
|
marginal graft |
8 |
|
microscopy, electron |
8 |
|
mitochondrion |
8 |
|
neovascularization, pathologic - prevention & control |
8 |
|
nitric oxide synthase type ii |
8 |
|
rac gtp-binding proteins - metabolism |
8 |
|
repressor proteins |
8 |
|
retinoblastoma protein - genetics - metabolism |
8 |
|
rna, messenger - genetics - metabolism |
8 |
|
splicing |
8 |
|
steatosis |
8 |
|
survival |
8 |
|
survival analysis |
8 |
|
transcription factors - genetics - metabolism - physiology |
8 |
|
treatment outcome |
8 |
|
vascular endothelial growth factor a - metabolism |
8 |
|
alanine transaminase - blood |
7 |
|
anti-steatosis |
7 |
|
antineoplastic agents - pharmacology |
7 |
|
apoptosis - drug effects |
7 |
|
beta catenin - genetics |
7 |
|
cadherins - metabolism |
7 |
|
cancer metastasis |
7 |
|
carcinoma, hepatocellular - blood supply - drug therapy - pathology |
7 |
|
carcinoma, hepatocellular - drug therapy - physiopathology - secondary |
7 |
|
carcinoma, hepatocellular - enzymology - genetics |
7 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology - virology |
7 |
|
carcinoma, hepatocellular - genetics - mortality - secondary |
7 |
|
caveolin 1 - genetics - metabolism |
7 |
|
caveolin-1 |
7 |
|
cell survival signaling |
7 |
|
cell transformation, neoplastic - metabolism |
7 |
|
chemokine cxcl10 - metabolism |
7 |
|
clone cells |
7 |
|
cyclin d1 - genetics |
7 |
|
disease-free survival |
7 |
|
dna-binding proteins - metabolism |
7 |
|
endothelial cells - drug effects |
7 |
|
endothelin-1 - genetics |
7 |
|
enzyme-linked immunosorbent assay |
7 |
|
epithelial cells - metabolism - physiology |
7 |
|
fatty liver - pathology - surgery |
7 |
|
gene expression regulation, neoplastic - genetics |
7 |
|
gene silencing |
7 |
|
glycogen synthase kinase 3 - metabolism |
7 |
|
graft rejection - blood - drug therapy - pathology |
7 |
|
graft survival - drug effects |
7 |
|
hepatic microcirculation |
7 |
|
hong kong - epidemiology |
7 |
|
hypoxia-inducible factor 1, alpha subunit - metabolism |
7 |
|
immunosuppressive agents - pharmacology |
7 |
|
in situ nick-end labeling |
7 |
|
inhibitor of differentiation protein 1 - antagonists & inhibitors - genetics - metabolism |
7 |
|
liver neoplasms - drug therapy - physiopathology - secondary |
7 |
|
liver neoplasms - enzymology - genetics |
7 |
|
liver neoplasms - genetics - metabolism - pathology - virology |
7 |
|
liver neoplasms - genetics - mortality - pathology |
7 |
|
liver neoplasms, experimental - blood supply - drug therapy - pathology |
7 |
|
macrophage |
7 |
|
matrix metalloproteinase 9 - metabolism |
7 |
|
microarray analysis - methods |
7 |
|
mir-23a |
7 |
|
neoplasm invasiveness - genetics |
7 |
|
neoplasm proteins - genetics |
7 |
|
neovascularization, pathologic - drug therapy |
7 |
|
neovascularization, pathologic - metabolism |
7 |
|
nitric oxide synthase - metabolism |
7 |
|
nuclear proteins - metabolism |
7 |
|
oligodeoxyribonucleotides, antisense - pharmacology - therapeutic use |
7 |
|
organ size |
7 |
|
peptidylprolyl isomerase - genetics |
7 |
|
proline-rich tyrosine kinase2 (pyk2) |
7 |
|
propylene glycols - therapeutic use |
7 |
|
proto-oncogene proteins c-akt |
7 |
|
rats, inbred lew |
7 |
|
rna interference |
7 |
|
rna, neoplasm - genetics |
7 |
|
signal transduction |
7 |
|
stat5 transcription factor - biosynthesis - genetics - metabolism |
7 |
|
statistics as topic |
7 |
|
structure-activity relationship |
7 |
|
survival rate |
7 |
|
tissue array analysis |
7 |
|
transcriptional activation - physiology |
7 |
|
transfection - methods |
7 |
|
transplantation, heterologous |
7 |
|
tumourigenesis |
7 |
|
twist transcription factor - metabolism |
7 |
|
up-regulation - genetics |
7 |
|
vascular endothelial growth factor a - genetics - metabolism - secretion |
7 |
|
xenograft model antitumor assays |
7 |
|
young adult |
7 |
|
adeno-associated virus |
6 |
|
akt signaling pathway |
6 |
|
angiopoietin-like 4 |
6 |
|
antigens, cd34 - metabolism |
6 |
|
antimetastasis |
6 |
|
autophagy |
6 |
|
bcl-2/beclin-1 |
6 |
|
bile |
6 |
|
biliary |
6 |
|
blotting, western |
6 |
|
cancer |
6 |
|
cancer metabolism |
6 |
|
cancer stem cells |
6 |
|
carcinoma |
6 |
|
carcinoma, hepatocellular - drug therapy - metabolism - secondary |
6 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology |
6 |
|
carcinoma, hepatocellular - genetics - mortality - pathology - surgery - therapy |
6 |
|
carcinoma, hepatocellular - genetics - prevention and control - secondary |
6 |
|
caspase 3 |
6 |
|
cd133 |
6 |
|
cd274 |
6 |
|
cdk1 inhibitor |
6 |
|
cdna microarray |
6 |
|
cell adhesion molecules |
6 |
|
cell cycle - genetics |
6 |
|
cell cycle proteins - genetics |
6 |
|
cell cycle proteins - metabolism |
6 |
|
chemokines |
6 |
|
chemoresistance |
6 |
|
cholangiocarcinoma |
6 |
|
cholangitis |
6 |
|
cisplatin |
6 |
|
coptidis rhizoma |
6 |
|
cyclin d1 - metabolism |
6 |
|
cyclin-dependent kinase inhibitor p21 |
6 |
|
cyclin-dependent kinase inhibitor p27 |
6 |
|
cytokines |
6 |
|
endothelin-1 - genetics - metabolism |
6 |
|
endothelium, vascular - pathology |
6 |
|
enzyme inhibitors - pharmacology |
6 |
|
epithelial-mesenchymal transition |
6 |
|
extracellular signal-regulated map kinases - metabolism |
6 |
|
f-actin |
6 |
|
focal adhesion kinase |
6 |
|
g1 phase - drug effects |
6 |
|
gene expression |
6 |
|
gene expression regulation |
6 |
|
gene expression regulation - physiology |
6 |
|
genes, p53 - genetics |
6 |
|
glycolysis |
6 |
|
graft injury |
6 |
|
graft survival |
6 |
|
heme oxygenase (decyclizing) - genetics |
6 |
|
hepatectomy - adverse effects |
6 |
|
hepatectomy - methods |
6 |
|
hepatocellular carcinoma (hcc) |
6 |
|
hepatocellular carcinomas |
6 |
|
hfe |
6 |
|
histone modifications |
6 |
|
homeodomain proteins - antagonists and inhibitors - genetics - metabolism |
6 |
|
homeodomain proteins - genetics - metabolism |
6 |
|
homeoprotein six1 |
6 |
|
hpyv6 |
6 |
|
hypertension, portal - etiology - physiopathology |
6 |
|
immune response |
6 |
|
inflammasomes |
6 |
|
inflammatory response |
6 |
|
interference |
6 |
|
intragraft gene expression profiles |
6 |
|
invasion |
6 |
|
kc |
6 |
|
kidney neoplasms - genetics - prevention and control - secondary |
6 |
|
ligation |
6 |
|
lipocalins |
6 |
|
liver - blood supply - metabolism - pathology - surgery |
6 |
|
liver - blood supply - pathology |
6 |
|
liver circulation - physiology |
6 |
|
liver cirrhosis |
6 |
|
liver neoplasms - blood supply - surgery - ultrastructure |
6 |
|
liver neoplasms - genetics - mortality - pathology - surgery - therapy |
6 |
|
liver neoplasms, experimental - drug therapy - metabolism - pathology |
6 |
|
liver neoplasms, experimental - genetics - pathology - prevention and control |
6 |
|
liver neoplasms, experimental - metabolism - pathology - surgery |
6 |
|
liver transplantation - adverse effects - pathology - physiology |
6 |
|
liver transplantation - pathology |
6 |
|
liver transplantation - pathology - physiology |
6 |
|
living donors |
6 |
|
lung neoplasms - etiology - metabolism - secondary |
6 |
|
m2 macrophages |
6 |
|
malignancy |
6 |
|
map kinase signaling system - drug effects |
6 |
|
matrix stiffness |
6 |
|
mechanoepigenetics |
6 |
|
microcirculation |
6 |
|
mitochondria, liver - pathology |
6 |
|
mitogen-activated protein kinase 1 - antagonists & inhibitors - metabolism |
6 |
|
mitogen-activated protein kinase 3 - antagonists & inhibitors - metabolism |
6 |
|
mtor |
6 |
|
neoplasm metastasis |
6 |
|
neoplasm recurrence, local - etiology - metabolism - pathology |
6 |
|
neutrophil |
6 |
|
nitric oxide synthase - genetics - metabolism |
6 |
|
nitric oxide synthase type iii |
6 |
|
organ size - physiology |
6 |
|
p21/waf1 |
6 |
|
p53 |
6 |
|
pathologic tumour-node-metastasis (ptnm) stage |
6 |
|
pdx models |
6 |
|
phosphatidylinositol 3-kinases - antagonists & inhibitors - metabolism |
6 |
|
phosphatidylinositol 3-kinases - metabolism |
6 |
|
phosphorylation - drug effects |
6 |
|
pkm2 |
6 |
|
polyomavirus |
6 |
|
portal pressure - physiology |
6 |
|
post-lt surveillance |
6 |
|
prmt6 |
6 |
|
prognosis |
6 |
|
prognostic predictor |
6 |
|
progression |
6 |
|
proliferating cell nuclear antigen |
6 |
|
proliferating cell nuclear antigen - analysis |
6 |
|
protein-serine-threonine kinases - metabolism |
6 |
|
proto-oncogene proteins - metabolism |
6 |
|
rac gtp-binding proteins - chemistry - metabolism |
6 |
|
rap1 |
6 |
|
regional blood flow - physiology |
6 |
|
reperfusion injury - pathology |
6 |
|
rna, small interfering - pharmacology |
6 |
|
ro/rock signaling |
6 |
|
ro3306 |
6 |
|
short hairpin rna (shrna) |
6 |
|
six1 |
6 |
|
small-for-size fatty liver |
6 |
|
sorafenib |
6 |
|
thbs2 |
6 |
|
therapeutic |
6 |
|
time factors |
6 |
|
transplantation, isogeneic |
6 |
|
tumor suppressor gene |
6 |
|
tumor suppressor protein p53 - metabolism |
6 |
|
tumor suppressor proteins - metabolism |
6 |
|
venous infiltration |
6 |
|
warburg effect |
6 |
|
wound healing |
6 |
|
acute-phase reaction |
5 |
|
acute-phase reaction - metabolism - pathology |
5 |
|
adenosine - chemistry |
5 |
|
adenosinergic signaling pathway |
5 |
|
aggressiveness |
5 |
|
akt |
5 |
|
akt survival pathway |
5 |
|
aldose reductase |
5 |
|
allergology and immunology |
5 |
|
allopurinol - chemistry |
5 |
|
alpps |
5 |
|
animal experiment |
5 |
|
animal models |
5 |
|
anti-cancer |
5 |
|
antibody therapy |
5 |
|
anxa3 |
5 |
|
apolipoprotein c-iii |
5 |
|
apolipoproteins c - metabolism |
5 |
|
aspartate aminotransferases - blood |
5 |
|
biomarker |
5 |
|
biopsy |
5 |
|
blood loss, surgical - prevention & control |
5 |
|
cancer biomarker |
5 |
|
carbon tetrachloride |
5 |
|
carcinoma, hepatocellular - enzymology - pathology - ultrastructure |
5 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology - secondary |
5 |
|
carcinoma, hepatocellular - metabolism - mortality - secondary |
5 |
|
carcinoma, hepatocellular - mortality - surgery |
5 |
|
carcinoma, squamous cell - genetics - pathology |
5 |
|
carrier proteins - genetics |
5 |
|
ccaat-enhancer-binding proteins - physiology |
5 |
|
cell cycle |
5 |
|
cell cycle - drug effects |
5 |
|
cell fusion |
5 |
|
cell invasion |
5 |
|
cell migration |
5 |
|
cell motility |
5 |
|
cell movement - physiology |
5 |
|
chemicals and cas registry numbers |
5 |
|
chemokine cxcl2 |
5 |
|
chemokines, cxc - metabolism |
5 |
|
computer systems |
5 |
|
coptidis rhizoma aqueous extract |
5 |
|
cyclooxygenase-2 |
5 |
|
cytokines - blood - genetics |
5 |
|
dna damage |
5 |
|
dna primers - chemistry |
5 |
|
dna probes |
5 |
|
dna-binding proteins - physiology |
5 |
|
docosahexaenoic acid |
5 |
|
docosahexaenoic acids - pharmacology |
5 |
|
e-cadherin |
5 |
|
early growth response protein 1 |
5 |
|
endothelin-1 - blood - genetics |
5 |
|
endothelin-1 - metabolism |
5 |
|
energy metabolism - drug effects - physiology |
5 |
|
entpd1/cd39 |
5 |
|
enzyme activity |
5 |
|
epidermal growth factor - metabolism |
5 |
|
epithelial-mesenchymal transition - physiology |
5 |
|
et5e/cd73 |
5 |
|
etoposide |
5 |
|
evaluation studies as topic |
5 |
|
extracellular adenosine |
5 |
|
fascin |
5 |
|
fibrosis - drug therapy - pathology |
5 |
|
focal adhesion kinase 2 - metabolism - physiology |
5 |
|
gardenia |
5 |
|
gene expression regulation, neoplastic |
5 |
|
gene therapy |
5 |
|
glucagon - blood |
5 |
|
glutathione - chemistry |
5 |
|
graft survival - drug effects - genetics |
5 |
|
graft survival - drug effects - immunology - physiology |
5 |
|
graft survival - physiology |
5 |
|
grp78 |
5 |
|
heme oxygenase (decyclizing) - biosynthesis |
5 |
|
hepatic ischemia reperfusion injury |
5 |
|
hepatic senescence |
5 |
|
hepatic steatosis |
5 |
|
hepatic stellate cell (hsc) |
5 |
|
hepatic stellate cells |
5 |
|
hepatocytes - cytology |
5 |
|
hospital mortality |
5 |
|
hsp70 heat-shock proteins - genetics |
5 |
|
hsp70 heat-shock proteins - metabolism |
5 |
|
hypertension, portal - etiology - prevention & control |
5 |
|
hypoglycemic agents - pharmacology |
5 |
|
hypoxia |
5 |
|
id-1 |
5 |
|
immediate-early proteins |
5 |
|
immediate-early proteins - metabolism |
5 |
|
immunosuppressive agents - administration and dosage |
5 |
|
insulin - chemistry - pharmacology |
5 |
|
insulin receptor substrate proteins |
5 |
|
intercellular signaling peptides and proteins - metabolism |
5 |
|
interleukin-10 - biosynthesis |
5 |
|
intracellular signaling peptides and proteins |
5 |
|
ir injury |
5 |
|
iridoid glycosides |
5 |
|
iridoids |
5 |
|
ketone bodies - blood |
5 |
|
liver - anatomy & histology - drug effects - ultrastructure |
5 |
|
liver - anatomy & histology - pathology - physiopathology |
5 |
|
liver - drug effects - injuries - metabolism |
5 |
|
liver - metabolism - ultrastructure |
5 |
|
liver - pathology |
5 |
|
liver - physiology - surgery |
5 |
|
liver cell carcinoma |
5 |
|
liver cirrhosis, experimental - surgery |
5 |
|
liver fibrosis |
5 |
|
liver neoplasms - blood - surgery |
5 |
|
liver neoplasms - enzymology - pathology - ultrastructure |
5 |
|
liver neoplasms - metabolism - mortality - pathology |
5 |
|
liver neoplasms - mortality - surgery |
5 |
|
liver neoplasms - pathology - surgery |
5 |
|
liver remnant |
5 |
|
liver transplantation - adverse effects |
5 |
|
liver transplantation - immunology |
5 |
|
liver transplantation - methods |
5 |
|
liver transplantation - physiology |
5 |
|
map kinase signaling system |
5 |
|
map kinase signaling system - drug effects - physiology |
5 |
|
mapk |
5 |
|
matrix metalloproteinase-12 |
5 |
|
microfilament proteins - genetics |
5 |
|
microrna |
5 |
|
micrornas - metabolism |
5 |
|
mir-21 |
5 |
|
models, animal |
5 |
|
momp |
5 |
|
mouth neoplasms - genetics - pathology |
5 |
|
mri |
5 |
|
multidrug resistance protein 1 |
5 |
|
neutrophils |
5 |
|
neutrophils migration |
5 |
|
nf-kappa b - metabolism |
5 |
|
nf-κb signaling |
5 |
|
non-coding rna |
5 |
|
nuclear factor-κb |
5 |
|
oligonucleotide array sequence analysis |
5 |
|
organ preservation |
5 |
|
organ preservation solutions - chemistry |
5 |
|
oscc |
5 |
|
oxygenation |
5 |
|
oxylab po2 |
5 |
|
p38 mitogen-activated protein kinases - metabolism |
5 |
|
phosphoproteins - physiology |
5 |
|
portal vein |
5 |
|
postoperative complications |
5 |
|
postoperative complications - prevention & control |
5 |
|
prospective studies |
5 |
|
protein-serine-threonine kinases - physiology |
5 |
|
protein-tyrosine kinases - physiology |
5 |
|
proteins - genetics |
5 |
|
proteins - metabolism |
5 |
|
proto-oncogene proteins - physiology |
5 |
|
raf kinases - metabolism |
5 |
|
raffinose - chemistry |
5 |
|
receptors, endothelin - genetics |
5 |
|
regorafenib |
5 |
|
regulatory t cells |
5 |
|
reperfusion injury - drug therapy |
5 |
|
reperfusion injury - metabolism - physiopathology |
5 |
|
rho-associated kinases - analysis - metabolism |
5 |
|
signal transduction - drug effects - physiology |
5 |
|
sirolimus - administration and dosage |
5 |
|
small-for-size graft |
5 |
|
smoking |
5 |
|
somatostatin - therapeutic use |
5 |
|
sorafenib resistance |
5 |
|
stem cell |
5 |
|
sterol regulatory element binding protein 1 |
5 |
|
stress, mechanical |
5 |
|
surgery medical sciences |
5 |
|
t cell exhaustion |
5 |
|
topoisomerase 1 |
5 |
|
transcription factors - physiology |
5 |
|
transferrin - analysis |
5 |
|
transplantation, homologous |
5 |
|
tumor progression |
5 |
|
tumor-initiating cell |
5 |
|
up-regulation - physiology |
5 |
|
upr pathway |
5 |
|
vasoconstriction - physiology |
5 |
|
ω-3 fatty acids |
5 |
|
actins - metabolism |
4 |
|
activated hepatic stellate cells |
4 |
|
adenosine |
4 |
|
allopurinol |
4 |
|
antigen spreading |
4 |
|
apoa-1 |
4 |
|
asb4 |
4 |
|
b-value |
4 |
|
biodegradation |
4 |
|
biomaterial |
4 |
|
bregs |
4 |
|
cancer vaccines |
4 |
|
carcinoma, hepatocellular - immunology - pathology - therapy |
4 |
|
caspase |
4 |
|
cd8+t cells |
4 |
|
cell differentiation |
4 |
|
cell hypoxia - drug effects - physiology |
4 |
|
cellular immune response |
4 |
|
chemoembolization |
4 |
|
clinical outcomes |
4 |
|
complement component |
4 |
|
contrast media |
4 |
|
core binding factor alpha 1 subunit - metabolism - physiology |
4 |
|
cox-2 |
4 |
|
ctls |
4 |
|
cyclodextrins - administration and dosage - chemistry - pharmacokinetics |
4 |
|
cyclooxygenase 2 |
4 |
|
cytokine receptor gp130 - metabolism |
4 |
|
dendritic cells - immunology |
4 |
|
diagnosis prediction |
4 |
|
dialysis solutions - diagnostic use |
4 |
|
dialyzate |
4 |
|
diffusion time |
4 |
|
dna - administration and dosage - chemistry - pharmacokinetics |
4 |
|
dose-response relationship, drug |
4 |
|
drug carriers - chemistry |
4 |
|
drug screening assays, antitumor - methods |
4 |
|
drug-induced liver injury - etiology - metabolism - pathology - surgery |
4 |
|
early-phase |
4 |
|
folate |
4 |
|
gastroenterology |
4 |
|
gene expression regulation - drug effects - physiology |
4 |
|
glutamine metabolism |
4 |
|
glutathione |
4 |
|
golgi apparatus - physiology |
4 |
|
graft survival - drug effects - physiology |
4 |
|
hcc invasiveness |
4 |
|
hcc recurrence |
4 |
|
hemoglobin-based oxygen carrier |
4 |
|
hemostasis, surgical |
4 |
|
hepatic bipotent cells |
4 |
|
hepatic ischemia reperfusion |
4 |
|
hepatocytes - drug effects - metabolism |
4 |
|
hepatocytes - metabolism - pathology - transplantation |
4 |
|
hepatotoxicity |
4 |
|
hif-1α |
4 |
|
homeostasis - physiology |
4 |
|
hpd |
4 |
|
hsp70 heat-shock proteins - genetics - metabolism |
4 |
|
humoral immune response |
4 |
|
hydroge |
4 |
|
hypoxia-inducible factor 1, alpha subunit |
4 |
|
hypoxic t6-hscs |
4 |
|
imines - chemistry |
4 |
|
immunity |
4 |
|
immunologic memory - immunology |
4 |
|
immunology and microbiology section |
4 |
|
in vivo test |
4 |
|
inactivated vaccine |
4 |
|
indomethacin - pharmacology |
4 |
|
inflammasome |
4 |
|
inflammatory responses |
4 |
|
insulin - pharmacology |
4 |
|
interleukin-10 - deficiency - genetics - immunology - metabolism |
4 |
|
interleukin-6 - genetics - metabolism |
4 |
|
intraperitoneal enhancement |
4 |
|
intravital imaging |
4 |
|
ischemic injury |
4 |
|
isoenzymes - antagonists & inhibitors - metabolism |
4 |
|
laparoscopic liver resection |
4 |
|
lef1 |
4 |
|
lipid metabolism |
4 |
|
liver - drug effects - pathology |
4 |
|
liver circulation - drug effects |
4 |
|
liver function tests |
4 |
|
liver neoplasms - metabolism - pathology - surgery |
4 |
|
liver regeneration |
4 |
|
liver steatosis |
4 |
|
lliver neoplasms |
4 |
|
macrophage activation |
4 |
|
magnetic resonance imaging - methods |
4 |
|
mangiferin |
4 |
|
mdsc |
4 |
|
mdscs |
4 |
|
melanoma - drug therapy - genetics - metabolism |
4 |
|
mesothelioma |
4 |
|
mice, knockout |
4 |
|
migration |
4 |
|
mir-1246 |
4 |
|
mir-200a |
4 |
|
modified vaccinia tiantan |
4 |
|
mrna vaccine |
4 |
|
mtor signaling |
4 |
|
myosin-light-chain phosphatase - metabolism |
4 |
|
nf-κb |
4 |
|
notch signaling |
4 |
|
open liver resection |
4 |
|
organ preservation - methods |
4 |
|
organ preservation solutions |
4 |
|
pdgf-bb |
4 |
|
peritoneal adhesion |
4 |
|
peritoneal cavity |
4 |
|
peritoneal dialysis |
4 |
|
peritoneal dialysis fluid |
4 |
|
phenotype |
4 |
|
phosphorylation |
4 |
|
pi3-kinase/akt |
4 |
|
polyethylenimine |
4 |
|
postoperative cytokines |
4 |
|
pringle manoeuvre |
4 |
|
propylene glycols - pharmacology - therapeutic use |
4 |
|
prostaglandin-endoperoxide synthases - metabolism |
4 |
|
prostatic intraepithelial neoplasia - genetics - metabolism - pathology |
4 |
|
prostatic neoplasms - drug therapy - genetics - metabolism - pathology |
4 |
|
proteomics |
4 |
|
pseudopodia - metabolism |
4 |
|
raffinose |
4 |
|
rat |
4 |
|
reactive oxygen species |
4 |
|
reperfusion injury - physiopathology |
4 |
|
response marker |
4 |
|
restricted diffusion |
4 |
|
rho-associated kinases - metabolism |
4 |
|
rodent liver |
4 |
|
sars-cov-2 |
4 |
|
small-for-size fatty graft injury |
4 |
|
steatotic liver graft |
4 |
|
stereotactic body radiotherapy |
4 |
|
stress |
4 |
|
stress fibers - metabolism |
4 |
|
sulfonamides - pharmacology |
4 |
|
therapeutic potential |
4 |
|
therapeutic target |
4 |
|
tissue adhesions - diagnosis |
4 |
|
tnp-470 |
4 |
|
transmembrane protein 47 |
4 |
|
tumor necrosis factor-alpha - genetics - metabolism |
4 |
|
tumor-suppressive protein |
4 |
|
tumour recurrence |
4 |
|
tyrosine catabolism |
4 |
|
ultrastructure |
4 |
|
vaccination |
4 |
|
vascular endothelial growth factors - biosynthesis - metabolism |
4 |
|
vegf |
4 |
|
vhl |
4 |
|
virotherapy |
4 |
|
wnt signalling |
4 |
|
wt1 |
4 |
|
β-cyclodextrin |
4 |
|
adenovirus |
3 |
|
alternative splicing events |
3 |
|
androgens - pharmacology |
3 |
|
animal cell |
3 |
|
antigens, cd31 - analysis |
3 |
|
antineoplastic activity |
3 |
|
antiviral agents - therapeutic use |
3 |
|
apoptosis - physiology |
3 |
|
beta catenin - analysis |
3 |
|
blood sampling |
3 |
|
body weight |
3 |
|
cadherins - analysis |
3 |
|
cancer hallmarks |
3 |
|
carcinoma, hepatocellular - complications - drug therapy - metabolism |
3 |
|
carcinoma, hepatocellular - drug therapy - genetics - mortality |
3 |
|
caspases - analysis |
3 |
|
cell count |
3 |
|
cell delivery |
3 |
|
cell division - drug effects |
3 |
|
cell movement - drug effects |
3 |
|
circulating tumor cell |
3 |
|
cirrhosis |
3 |
|
cisplatin resistance |
3 |
|
ctla-4 |
3 |
|
cysteine - analogs and derivatives - pharmacology - therapeutic use |
3 |
|
cytoskeleton - drug effects |
3 |
|
cytotoxic t lymphocytes |
3 |
|
damage |
3 |
|
dna vaccine |
3 |
|
early allograft dysfunction |
3 |
|
epcs |
3 |
|
fibronectin |
3 |
|
fibrosis |
3 |
|
gadolinium |
3 |
|
garlic - chemistry |
3 |
|
glioblastoma |
3 |
|
hepatic i/r injury |
3 |
|
hepatic ischaemiareperfusion injury |
3 |
|
hepatic ischemia/reperfusion |
3 |
|
htertc27 |
3 |
|
immune checkpoint blockade |
3 |
|
immunology |
3 |
|
in vivo applications |
3 |
|
interferon-alpha - therapeutic use |
3 |
|
intrathecal morphine |
3 |
|
ip10 |
3 |
|
lactate |
3 |
|
liver neoplasms - complications - drug therapy - metabolism |
3 |
|
liver neoplasms - drug therapy - genetics - mortality |
3 |
|
liver transplantation using steatotic graft |
3 |
|
living-related liver donors |
3 |
|
magnet‐driven |
3 |
|
metabolism and immune cells |
3 |
|
microrobots |
3 |
|
molecular imaging |
3 |
|
neoplasm metastasis - prevention & control |
3 |
|
oncology |
3 |
|
orchiectomy |
3 |
|
pd-1 |
3 |
|
pd1 |
3 |
|
pd1-based vaccination |
3 |
|
photoacoustic imaging |
3 |
|
proliferation |
3 |
|
propylene glycols - administration & dosage - toxicity |
3 |
|
prostate cancer |
3 |
|
prostate-specific antigen - blood |
3 |
|
prostatic neoplasms - chemistry - drug therapy - pathology |
3 |
|
prostatic neoplasms - drug therapy - enzymology - pathology |
3 |
|
proto-oncogene proteins c-bcl-2 - analysis |
3 |
|
rapamycin |
3 |
|
rhoa |
3 |
|
rhoa gtp-binding protein - antagonists & inhibitors |
3 |
|
soluble pd1-based vaccination |
3 |
|
sphingosine - analogs & derivatives - pharmacology |
3 |
|
t cell immunity |
3 |
|
tregs |
3 |
|
tumor growth |
3 |
|
tumor metastasis |
3 |
|
twist1 antigen |
3 |
|
tyrosine transaminase - genetics |
3 |
|
vascular endothelial growth factor a - analysis |
3 |
|
yb1 |
3 |
|
yq23 |
3 |
|
adefovir |
2 |
|
akt3 |
2 |
|
alcoholic liver disease |
2 |
|
angiostatin |
2 |
|
animal model |
2 |
|
apparent diffusion coefficient |
2 |
|
b7.1 |
2 |
|
carbon tetrachloride (ccl 4) |
2 |
|
carcinoma, hepatocellular - drug therapy - metabolism - pathology |
2 |
|
ccl 4 |
2 |
|
chemokine |
2 |
|
covalently closed circular dna |
2 |
|
diffusion imaging |
2 |
|
diffusion tensor imaging |
2 |
|
diffusion-weighted imaging |
2 |
|
dna |
2 |
|
fractional anisotropy |
2 |
|
hemorrhage. |
2 |
|
heparanase |
2 |
|
hepatectomy. |
2 |
|
hepatic stellate cell |
2 |
|
hepatitis b core antigen |
2 |
|
hepatitis b surface antigen |
2 |
|
hepatocellular carcinoma metastasis |
2 |
|
ischemia/reperfusion injury |
2 |
|
ischemic reperfusion injury |
2 |
|
ivim |
2 |
|
kidney |
2 |
|
lipid |
2 |
|
lipids - analysis |
2 |
|
liver - cancer. |
2 |
|
liver -- cancer -- diagnosis. |
2 |
|
liver -- cancer -- prognosis. |
2 |
|
liver -- cancer -- treatment. |
2 |
|
liver cirrhosis - diagnosis - metabolism |
2 |
|
liver cirrhosis, experimental - chemically induced - diagnosis |
2 |
|
liver neoplasms - drug therapy - metabolism - pathology |
2 |
|
lung neoplasms - drug therapy - metabolism - secondary |
2 |
|
magnetic resonance spectroscopy - methods |
2 |
|
matrix metallopeptidase |
2 |
|
mir-29b |
2 |
|
non-alcoholic fatty liver disease |
2 |
|
ppar gamma - agonists - metabolism |
2 |
|
pparg |
2 |
|
proton magnetic resonance spectroscopy ( 1h mrs) |
2 |
|
protons - diagnostic use |
2 |
|
saturated fatty acid |
2 |
|
sobriety |
2 |
|
t 1, t 2 relaxometry |
2 |
|
therapy |
2 |
|
thiazolidinediones - pharmacology |
2 |
|
tissue inhibitors of metalloproteinase |
2 |
|
unsaturated fatty acid |
2 |
|
3d/4d printing |
1 |
|
ablation therapy |
1 |
|
adjuvant chemoradiotherapy |
1 |
|
aggregation-induced emission |
1 |
|
array-cgh |
1 |
|
autolysosome |
1 |
|
bmi1 |
1 |
|
breast cancer |
1 |
|
chemosensing |
1 |
|
colorectal tumor |
1 |
|
computed tomography |
1 |
|
consensus |
1 |
|
consensus development |
1 |
|
cryl1 |
1 |
|
cxcr3 |
1 |
|
cytokine |
1 |
|
diagnosis |
1 |
|
erα signaling |
1 |
|
estrogen receptor α |
1 |
|
europe |
1 |
|
fibre-based wearable |
1 |
|
hepatic carcinogenesis |
1 |
|
hepatoblastoma |
1 |
|
hepatocytes |
1 |
|
history |
1 |
|
homozygous deletions |
1 |
|
human |
1 |
|
immune escape |
1 |
|
immune responses |
1 |
|
liver ischemia reperfusion injury |
1 |
|
luminal phenotype |
1 |
|
lysosome |
1 |
|
macrophages |
1 |
|
metabolism |
1 |
|
mitochondria |
1 |
|
non-alcoholic fatty liver diseases |
1 |
|
non-alcoholic steatohepatitis |
1 |
|
notch3 |
1 |
|
p38 mapk |
1 |
|
polylactic acid |
1 |
|
pro-inflammatory cytokines |
1 |
|
quality control system |
1 |
|
smad7 |
1 |
|
soluble axl |
1 |
|
somatic variants |
1 |
|
steatohepatitis |
1 |
|
stemness |
1 |
|
surgical oncology |
1 |
|
therapeutic strategies |
1 |
|
three-dimensional printing |
1 |
|
three-dimensional visualization |
1 |
|
transplant oncology |
1 |
|
transplantation |
1 |
|
treatment |
1 |
|
tumour suppressor |
1 |
|
tumour suppressor gene |
1 |
|
unidirectional draining |
1 |
|
α-fetoprotein |
1 |
|
βcatenin |
1 |
